C07J 19/00
Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17
Official title: Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
C07J19/00 (Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17) appears on 107 US grants and 46 published applications in this corpus.
Search patents in C07J- Granted patents
- 107
- Published applications
- 46
- Assignees
- 80
- Inventors
- 250
- Latest grant
- 9 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 15 | 0 |
| 1977 | 11 | 0 |
| 1978 | 7 | 0 |
| 1979 | 2 | 0 |
| 1980 | 5 | 0 |
| 1981 | 2 | 0 |
| 1982 | 3 | 0 |
| 1983 | 3 | 0 |
| 1984 | 2 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 3 |
| 2004 | 2 | 0 |
| 2005 | 0 | 2 |
| 2006 | 1 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 1 |
| 2009 | 1 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 3 |
| 2013 | 2 | 6 |
| 2014 | 3 | 2 |
| 2015 | 3 | 1 |
| 2016 | 3 | 4 |
| 2017 | 2 | 2 |
| 2018 | 2 | 1 |
| 2019 | 2 | 2 |
| 2020 | 2 | 6 |
| 2021 | 4 | 2 |
| 2022 | 1 | 1 |
| 2023 | 2 | 0 |
| 2024 | 0 | 4 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
Recent patents
- Inhibition of interaction between OCT4 and MAPKAPK2 or DNA-PKcs to regulate c-MYC in cancer9 Dec 2025US 12,491,191 B2Texas Tech University System
- 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure22 Aug 2023US 11,730,746 B2CVie Therapeutics Limited
- Compounds for treating neurodegenerative disorders25 Apr 2023US 11,634,452 B2Centre National de la Recherche Scientifique (CNRS)
- Certain chemical entities, compositions, and methods10 May 2022US 11,325,940 B2Neupharma, Inc.
- Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms17 Aug 2021US 11,091,510 B2Enkang Pharmaceuticals (Guangzhou), Ltd.
- Cardiac steroid derivatives19 Dec 2024US 2024/0417425 A1Yissum Research Development Company of the Hebrew University of Jerusalem
- Use of st-type lipid compounds in preparation of nucleic acid delivery reagent and related product5 Sep 2024US 2024/0293551 A1Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
- Compounds for altering levels of one or more nka alpha subunits and their use in treating prion diseases or brain diseases associated with cellular prion protein23 May 2024US 2024/0166684 A1
- Storage stable caged haptens4 Jan 2024US 2024/0002428 A1Ventana Medical Systems, Inc.
- Inhibition of interaction between oct4 and mapkapk2 or dna-pkcs to regulate c-myc in cancer28 Jul 2022US 2022/0233554 A1Texas Tech University System
Most cited
By later US patents
- Digoxigenin derivatives and use thereof69US 5,198,537 ABoehringer Mannheim GmbH · 1993
- Compounds for enzyme amplification assay52US 4,067,774 ASyva Company · 1978
- Enzyme bound corticosteroids33US 4,282,325 ASyva Company · 1981
- Glycosides having sweetness27US 4,084,010 ANippon Shoji Kaisha, Ltd. · 1978
- Radioimmunoassay for determining the digoxin content of a sample25US 3,981,982 AAbbott Laboratories · 1976